Benitec Biopharma
BNTC
88 hedge funds and large institutions have $346M invested in Benitec Biopharma in 2026 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 35 increasing their positions, 13 reducing their positions, and 8 closing their positions.
213% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 8
169% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 13
22% more funds holding
Funds holding: 72 → 88 (+16)
1.05% more ownership
Funds ownership: 93.5% → 94.55% (+1.1%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
19% less capital invested
Capital invested by funds: $427M → $346M (-$80.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Simplify Asset Management
Las Vegas,
Nevada
|
+$4.76M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$4.63M |
| 3 |
BlackRock
New York
|
+$2.24M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$2.09M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SL
Siren LLC
Greenwich,
Connecticut
|
-$10.4M |
| 2 |
LP
Longaeva Partners
Chicago,
Illinois
|
-$1.91M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$1.36M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.26M |
| 5 |
AIC
AWM Investment Company
New York
|
-$1.1M |
BNTC Hedge Fund Activity: Q1 2026 in Review
88 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q1 2026, worth a combined $346M — down 19% from $427M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new BNTC positions and 8 closed out — a net gain of 17 holders — while 35 added to existing stakes and 13 trimmed.
The largest buyer was Simplify Asset Management, adding an estimated $4.76M. The largest seller was Siren LLC, exiting entirely with an estimated $10.4M sold.
- 88 institutional investors held Benitec Biopharma (BNTC) as of Q1 2026, up from 72 in Q4 2025.
- Funds reported $346M of Benitec Biopharma stock for Q1 2026, down 19% quarter-over-quarter.
- 25 funds opened new Benitec Biopharma positions in Q1 2026 and 8 closed out, a net change of +17 holders.
- The largest Benitec Biopharma buyer in Q1 2026 was Simplify Asset Management, an estimated $4.76M added.
- The largest Benitec Biopharma seller in Q1 2026 was Siren LLC, an estimated $10.4M sold.
Based on aggregated 13F filings for Q1 2026.